Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States.
Olalekan O OluwoleMarkqayne D RayKatherine L RosettieGraeme BallJorge JacobS Pinar BilirAnik R PatelCaron A JacobsonPublished in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2024)
Given the robustness of the model results and sensitivity analyses, axi-cel is expected to be a cost-effective treatment in 3L+ r/r FL.